Oncimmune Holdings Ord 1p
ONC: 118.65 0.00 (0.00%)
| Bid Price | 117.00 | High Price | 0.00 |
|---|---|---|---|
| Ask Price | 120.00 | Low Price | 0.00 |
| Open Price | 118.50 | Spread | 2.53% |
| Prev Close | 118.50 | Volume | 0.00 |
Oncimmune Holdings Ord 1p Share Price Chart
Intraday
Historic – 1 year
Oncimmune Holdings Ord 1p Share Price Information
| Name | Oncimmune Holdings Ord 1p | Epic | ONC |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology | ISIN | GB00BYQ94H38 |
| Activites | Oncimmune Holdings plc is a leading early cancer detection company, developing and commercialising its proprietary EarlyCDT platform technology. The Group has pioneered the development of tests based on the presence in the blood of autoantibodies against specific tumour associated antigens (TAAs) that have the potential to detect cancer up to 4 years earlier than other methods such as a chest X-ray or Spiral CT (computed tomography) and can be applied to a very wide range of solid tumour types. Oncimmune Limited was incorporated in 2002 as a spin out from the University of Nottingham focusing on the early detection of cancer. | Security Type | Equity |
Key numbers
| Latest Share Price (p) | 118.50 | Net Gearing (%) | -77.80 |
|---|---|---|---|
| Market Cap (£m) | 60.46 | Gross Gearing (%) | 13.18 |
| Shares in issue (m) | 51.02 | Debt Ratio | 3.90 |
| P/E Ratio | 0.00 | Debt-to-Equity Ratio | 0.27 |
| Divs per share (p) | 0.00 | Assets / Equity Ratio | 1.15 |
| Dividend Yield (%) | 0.00 | Price to book value | 6.21 |
| Dividend Cover | 0.00 | SROCE (%) | -88.94 |
| Earning per share (p) | 0.00 | EPS Growth (%) | |
| 52-week high / low (p) | 132.50 / 104.50 | DPS Growth (%) |
Oncimmune Holdings Ord 1p Broker Views
| Date | Broker | Rec. | Price | Old target price | New target price | Notes |
|---|---|---|---|---|---|---|
| 08 Nov | Beaufort Securities | Speculative Buy | 118.65 | Retains | ||
| 18 Jul | Beaufort Securities | Speculative Buy | 118.65 | Retains | ||
| 05 Jul | Beaufort Securities | Speculative Buy | 118.65 | Initiates/Starts |
Oncimmune Holdings Ord 1p Director Deals
Oncimmune Holdings Ord 1p Company News
FLASH: Oncimmune appoints Andrew Millet as CFO
Story provided by StockMarketWire.com
Oncimmune wins CE mark for EarlyCDT-Lung
Oncimmune Holdings has obtained the CE mark for the reagents used in EarlyCDT-Lung, an autoantibody blood test that can detect cancer up to four years earlier than other methods.
The CE mark certifies that the reagents used in EarlyCDT-Lung meet the strict EU standards of manufacturing and quality control dictated by the In Vitro Diagnostics Medical Devices Directive 98/79/EC (IVD Directive).
Story provided by StockMarketWire.com
FLASH: Oncimmune wins CE mark for EarlyCDT-Lung
Story provided by StockMarketWire.com
Oncimmune Holdings notes research agreements
Oncimmune Holdings has signed research agreements with Egybiotech, a private research company with a broad research portfolio in the areas of cancer research, and Aarhus University Hospital (“Aarhus”), Denmark.
Under these agreements, Egybiotech and Aarhus provide Oncimmune with prospectively collected blood samples and associated clinical data on each patient in order to further clinically validate the Company’s EarlyCDT platform technology in liver and ovarian cancer, respectively.
Oncimmune will use the samples to validate panels of autoantibodies as diagnostic tests capable of distinguishing between malignant and non-malignant liver and ovarian diseases, particularly at an early stage.
Story provided by StockMarketWire.com
FLASH: Oncimmune Holdings notes research agreements
Story provided by StockMarketWire.com